Outcomes of NAFLD and MAFLD: Results from a community-based, prospective cohort study

被引:90
作者
Niriella, Madunil Anuk [1 ]
Ediriweera, Dileepa Senajith [1 ]
Kasturiratne, Anuradhani [1 ]
De Silva, Shamila Thivanshi [1 ]
Dassanayaka, Anuradha Supun [1 ]
De Silva, Arjuna Priyadarshin [1 ]
Kato, Norihiro [2 ]
Pathmeswaran, Arunasalam [1 ]
Wickramasinghe, Ananda Rajitha [1 ]
de Silva, Hithanadura Janaka [1 ]
机构
[1] Univ Kelaniya, Fac Med, Kelaniya, Sri Lanka
[2] Natl Ctr Global Hlth & Med, Shinjuku Ku, Tokyo, Japan
来源
PLOS ONE | 2021年 / 16卷 / 02期
关键词
FATTY LIVER-DISEASE; FIBROSIS STAGE; RISK-FACTORS; MORTALITY; URBAN;
D O I
10.1371/journal.pone.0245762
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background The term "metabolic (dysfunction)-associated fatty liver disease" (MAFLD) is suggested alternative for "non-alcoholic fatty liver disease" (NAFLD), as it better reflects metabolic dysfunction. No study has compared outcomes of the two diagnostic criteria. Methods In an ongoing, community-based, cohort-study in suburban Sri Lanka, participants were randomly selected in 2007. They were reassessed in 2014 to evaluate new-onset metabolic traits (MTs) and cardiovascular-events (CVEs). Baseline characteristics, MTs and CVEs after 7-years were compared in NAFLD and MAFLD and vs. controls. Similarly, we compared these parameters in those excluded by the NAFLD definition but captured by the MAFLD definition and vice versa, and vs. controls. Findings Of 2985 recruited in 2007, 940 (31.5%) had NAFLD, 990 (33.1%) had MAFLD and 362 (12.1%) were controls. When compared to NAFLD, MAFLD captured an additional 2.9% and lost 1.3% individuals. At baseline, anthropometric and metabolic traits were similar in NAFLD and MAFLD. At follow-up in 7-years, the risk of having new-onset MTs and fatal/non-fatal CVEs were similar in the groups, but were significantly higher compared to controls. Those excluded by the NAFLD definition but captured by the MAFLD definition showed higher baseline MTs compared to those excluded by the MAFLD definition but captured by the NAFLD definition, and had substantially higher risk for having new-onset MTs and CVEs compared to controls. Interpretation Although NAFLD and MAFLD had similar MTs at baseline, and similar outcomes after 7-years, those who were excluded by the NAFLD definition but captured by the MAFLD definition seem at higher risk of adverse outcomes than those excluded by the MAFLD definition but captured by the NAFLD definition. Although the increase in the index population was small, redefining NAFLD as MAFLD seemed to improve clinical utility.
引用
收藏
页数:11
相关论文
共 24 条
[1]  
Angulo P, LIVER FIBROSIS NO OT
[2]   The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases [J].
Chalasani, Naga ;
Younossi, Zobair ;
Lavine, Joel E. ;
Charlton, Michael ;
Cusi, Kenneth ;
Rinella, Mary ;
Harrison, Stephen A. ;
Brunt, Elizabeth M. ;
Sanyal, Arun J. .
HEPATOLOGY, 2018, 67 (01) :328-357
[3]   How should we manage patients with non-alcoholic fatty liver disease in 2007? [J].
Chan, Henry L-Y ;
de Silva, H. Janaka ;
Leung, Nancy W-Y ;
Lim, Seng-Gee ;
Farrell, Geoffrey C. .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2007, 22 (06) :801-808
[4]   Nonalcoholic Fatty Liver Disease 2020: The State of the Disease [J].
Cotter, Thomas G. ;
Rinella, Mary .
GASTROENTEROLOGY, 2020, 158 (07) :1851-1864
[5]   Prevalence and risk factors for non-alcoholic fatty liver disease among adults in an urban Sri Lankan population [J].
Dassanayake, Anuradha S. ;
Kasturiratne, Anuradhani ;
Rajindrajith, Shaman ;
Kalubowila, Udaya ;
Chakrawarthi, Sureka ;
De Silva, Arjuna P. ;
Makaya, Miyuki ;
Mizoue, Tetsuya ;
Kato, Norihiro ;
Wickremasinghe, A. Rajitha ;
de Silva, H. Janaka .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2009, 24 (07) :1284-1288
[6]   Fatty liver, hypertension, and the metabolic syndrome [J].
Diehl, AM .
GUT, 2004, 53 (07) :923-924
[7]   Increased Risk of Mortality by Fibrosis Stage in Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis [J].
Dulai, Parambir S. ;
Singh, Siddharth ;
Patel, Janki ;
Soni, Meera ;
Prokop, Larry J. ;
Younossi, Zobair ;
Sebastiani, Giada ;
Ekstedt, Mattias ;
Hagstrom, Hannes ;
Nasr, Patrik ;
Stal, Per ;
Wong, Vincent Wai-Sun ;
Kechagias, Stergios ;
Hultcrantz, Rolf ;
Loomba, Rohit .
HEPATOLOGY, 2017, 65 (05) :1557-1565
[8]   Fibrosis Stage Is the Strongest Predictor for Disease-Specific Mortality in NAFLD After Up to 33 Years of Follow-Up [J].
Ekstedt, Mattias ;
Hagstrom, Hannes ;
Nasr, Patrik ;
Fredrikson, Mats ;
Stal, Per ;
Kechagias, Stergios ;
Hultcrantz, Rolf .
HEPATOLOGY, 2015, 61 (05) :1547-1554
[9]   A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement [J].
Eslam, Mohammed ;
Newsome, Philip N. ;
Sarin, Shiv K. ;
Anstee, Quentin M. ;
Targher, Giovanni ;
Romero-Gomez, Manuel ;
Zelber-Sagi, Shira ;
Wong, Vincent Wai-Sun ;
Dufour, Jean-Francois ;
Schattenberg, Joern M. ;
Kawaguchi, Takumi ;
Arrese, Marco ;
Valenti, Luca ;
Shiha, Gamal ;
Tiribelli, Claudio ;
Yki-Jarvinen, Hannele ;
Fan, Jian-Gao ;
Gronbaek, Henning ;
Yilmaz, Yusuf ;
Cortez-Pinto, Helena ;
Oliveira, Claudia P. ;
Bedossa, Pierre ;
Adams, Leon A. ;
Zheng, Ming-Hua ;
Fouad, Yasser ;
Chan, Wah-Kheong ;
Mendez-Sanchez, Nahum ;
Ahn, Sang Hoon ;
Castera, Laurent ;
Bugianesi, Elisabetta ;
Ratziu, Vlad ;
George, Jacob .
JOURNAL OF HEPATOLOGY, 2020, 73 (01) :202-209
[10]   Redefining non-alcoholic fatty liver disease: what's in a name? [J].
不详 .
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2020, 5 (05) :419-419